Cynosure Group LLC Decreases Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Cynosure Group LLC lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 16.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,269 shares of the medical instruments supplier’s stock after selling 656 shares during the period. Cynosure Group LLC’s holdings in LeMaitre Vascular were worth $301,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of LMAT. Huntington National Bank increased its stake in LeMaitre Vascular by 64.9% during the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 455 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of LeMaitre Vascular by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier’s stock worth $50,711,000 after acquiring an additional 7,737 shares during the last quarter. Franklin Resources Inc. increased its position in shares of LeMaitre Vascular by 8.2% during the fourth quarter. Franklin Resources Inc. now owns 13,678 shares of the medical instruments supplier’s stock worth $1,260,000 after purchasing an additional 1,032 shares in the last quarter. Alliancebernstein L.P. raised its stake in LeMaitre Vascular by 6.0% in the 4th quarter. Alliancebernstein L.P. now owns 22,584 shares of the medical instruments supplier’s stock valued at $2,081,000 after purchasing an additional 1,287 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in LeMaitre Vascular by 239.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 9,833 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 6,937 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Lake Street Capital raised their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Wells Fargo & Company began coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target for the company. Finally, Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Stock Performance

LMAT stock opened at $86.62 on Thursday. LeMaitre Vascular, Inc. has a one year low of $62.39 and a one year high of $109.58. The firm has a market cap of $1.95 billion, a PE ratio of 47.33, a PEG ratio of 2.22 and a beta of 0.89. The firm’s 50 day moving average price is $92.25 and its 200-day moving average price is $94.31.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. Equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend was Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.